Spark Therapeutics terminates collaboration agreement for the epilepsy project CG01 with CombiGene
October 14, 2023
CombiGene today announces that the company will regain the global rights for the epilepsy project CG01
CombiGene today announces that the company will regain the global rights for the epilepsy project CG01
CombiGene AB (publ) (“CombiGene”, the “Company”) today announces that the Company, after a thorough evaluation process,
Read CombiGene’s newsletter in English here or download the attachment. Ingeneious issue no 4 2023 mobile
In June, CombiGene and Spark Therapeutics held a bi-annual Joint Research Committee meeting in Stockholm, Sweden,
April – June 2023• Net sales: TSEK 1,788 (4,738).• Other operating revenues: TSEK 1,413 (9,800).• Profit
CombiGene AB (“CombiGene”, the “Company”) today announces that CEO Jan Nilsson will leave his position as
In January 2023, CombiGene AB (“CombiGene”, the “Company”) and the Danish company Zyneyro ApS announced a
Read CombiGene’s newsletter in English here or download the attachement. Ingeneious issue no 3 2023 Contacts
The following resolutions were passed at the annual general meeting (the “AGM”) of CombiGene AB (publ)
Read CombiGene’s newsletter in English here or download the attachement. Contacts Jan Nilsson, CEO Phone: +46